JP2018513215A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513215A5
JP2018513215A5 JP2018505542A JP2018505542A JP2018513215A5 JP 2018513215 A5 JP2018513215 A5 JP 2018513215A5 JP 2018505542 A JP2018505542 A JP 2018505542A JP 2018505542 A JP2018505542 A JP 2018505542A JP 2018513215 A5 JP2018513215 A5 JP 2018513215A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
fluorinated
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505542A
Other languages
English (en)
Japanese (ja)
Other versions
JP6776330B2 (ja
JP2018513215A (ja
Filing date
Publication date
Priority claimed from GBGB1506448.8A external-priority patent/GB201506448D0/en
Application filed filed Critical
Publication of JP2018513215A publication Critical patent/JP2018513215A/ja
Publication of JP2018513215A5 publication Critical patent/JP2018513215A5/ja
Application granted granted Critical
Publication of JP6776330B2 publication Critical patent/JP6776330B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505542A 2015-04-16 2016-04-15 抗菌化合物 Expired - Fee Related JP6776330B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506448.8A GB201506448D0 (en) 2015-04-16 2015-04-16 An antimicrobial compound
GB1506448.8 2015-04-16
PCT/GB2016/051053 WO2016166546A1 (en) 2015-04-16 2016-04-15 An antimicrobial compound

Publications (3)

Publication Number Publication Date
JP2018513215A JP2018513215A (ja) 2018-05-24
JP2018513215A5 true JP2018513215A5 (enExample) 2019-05-23
JP6776330B2 JP6776330B2 (ja) 2020-10-28

Family

ID=53298672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505542A Expired - Fee Related JP6776330B2 (ja) 2015-04-16 2016-04-15 抗菌化合物

Country Status (5)

Country Link
US (1) US10406166B2 (enExample)
EP (1) EP3283170A1 (enExample)
JP (1) JP6776330B2 (enExample)
GB (1) GB201506448D0 (enExample)
WO (1) WO2016166546A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992839A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
GB201613942D0 (en) * 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019222538A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Aminopyrimidines and aminopyridines as mertk inhibitors and their application in cancer treatment
AU2020240024B2 (en) 2019-03-18 2025-06-26 Enanta Pharmaceuticals, Inc Benzodiazepine derivatives as RSV inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
GB201915273D0 (en) 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
GB202010408D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
GB202102602D0 (en) 2021-02-24 2021-04-07 Reviral Ltd Pharmaceutical compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
WO2025153942A1 (en) 2024-01-16 2025-07-24 Pfizer Inc. Benzodiazepine pyrazolo carboxamides as n-protein inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
PL375860A1 (en) * 2002-09-20 2005-12-12 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
GB0406282D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US8039616B2 (en) 2005-09-19 2011-10-18 Astrazeneca Ab Benzodiazepine derivatives for treating hepatitis C infection

Similar Documents

Publication Publication Date Title
JP2018513215A5 (enExample)
JP2022124458A5 (enExample)
JP2015078220A5 (enExample)
CN112074519A8 (zh) 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
JP2017533968A5 (enExample)
JP2018519302A5 (enExample)
JP2012510458A5 (enExample)
JP2019518050A5 (enExample)
JP2018507877A5 (enExample)
JP2014504622A5 (enExample)
JP2020534263A5 (enExample)
JP2016527238A5 (enExample)
JP2017524025A5 (enExample)
JP2016525135A5 (enExample)
JP2013542261A5 (enExample)
JP2018516904A5 (enExample)
JP2016516043A5 (enExample)
JP2019527724A5 (enExample)
JP2016512563A5 (enExample)
CN111295372A (zh) 硝羟喹啉前药及其用途
JP2017517512A5 (enExample)
JP2014500296A5 (enExample)
JP2017529357A5 (enExample)
JP2016190843A5 (enExample)
JP2017519817A5 (enExample)